Navigation Links
Enterome In-licenses Novel Compounds From Vertex Pharmaceuticals to Treat Microbiome-related Inflammatory Bowel Diseases
Date:4/18/2016

PARIS and BOSTON, April 18, 2016 /PRNewswire/ --

First novel small molecule FimH antagonists to enter clinical development in 2016 

ENTEROME Bioscience SA, a pioneer in the development of pharmaceuticals and diagnostics based on the gut microbiome, has signed an exclusive worldwide license agreement with Vertex Pharmaceuticals Inc. (Nasdaq: VRTX) to research, develop and commercialize novel small molecule FimH antagonists for use in the treatment of inflammatory bowel diseases (IBD).

Enterome plans to take the lead compound in this program, known as EB 8018, into first human clinical trials during 2016 as well as a companion diagnostic to identify patients with inflammatory bowel diseases (IBD) who will benefit from their use.

Through application of its metagenomics platform, Enterome has identified a key bacterial species - adherent-invasive Escherichia coli (AIEC) - which is responsible for triggering inflammation in IBD. AIEC adheres to gut epithelial cells by virtue of FimH adhesion proteins on its cell surface, which bind to the CEACAM6 receptor on gut epithelial cells and allow the bacterial cells to invade the gut wall and proliferate. Research has shown that blocking FimH prevents the adherence and proliferation of AIEC, thereby reducing inflammation and providing new opportunities for the prevention and treatment of IBD.

"The rapid growth of evidence supporting the involvement of the microbiome in serious diseases is providing myriad new opportunities and targets for therapeutic intervention with small molecule drugs," commented Pierre Belichard, CEO of Enterome. "The unique insights we have gained on the roles of specific constituents of the gut microbiome brought through our metagenomics platform strongly supports the central role of AIEC in inflammatory bowel diseases. Through this in-licensing agreement we are delighted to gain access to these novel FimH antagonists including EB8018, which we intend to advance into clinical trials during 2016, and which we believe could be transformative for the management and treatment of IBD."

About Enterome 

Enterome is pioneering the development of novel pharmaceuticals and diagnostics to support personalized therapies in microbiome-related diseases such as Inflammatory Bowel Disease (IBD), cancer and metabolic diseases.

Enterome is also leading the development of new industry standards in gut microbiome quantitative and functional analysis. This technology leadership allows Enterome to open up the new field of therapeutic target discovery in the microbiome in order to address significant unmet medical needs.

Enterome has established partnerships with leading pharmaceutical companies and academic research institutes, including Johnson & Johnson Innovation/Janssen Biotech, Takeda and Abbvie in inflammatory bowel diseases; and the Mayo Clinic and Geisinger hospitals in metabolic disorders.

The Company was established in 2012 in Paris, France to develop the discoveries made by the INRA metagenomic platform. The Company has raised a total of €17.5 million from leading venture capital investors (Seventure Partners, Lundbeckfond Ventures & Omnes Capital) and two strategic investors (Shire & INRA transfer).

Additional information about Enterome is available through its website : http://www.enterome.com.

Contacts 
Pierre Belichard, CEO 
+33-1-75-77-27-87

David Dible / Mark Swallow / Marine Perrier, Citigate Dewe Rogerson 
+44-207-638-9571

enterome@citigatedr.co.uk

 



'/>"/>
SOURCE Enterome Bioscience SA
Copyright©2016 PR Newswire.
All rights reserved


Related medicine technology :

1. EnteroMedics to Host Second Quarter 2014 Financial Results and Business Update Conference Call
2. EnteroMedics to Participate in Canaccord Genuity 34th Annual Growth Conference
3. EnteroMedics Reports Second Quarter 2014 Financial Results
4. Health Care Equipment Equities under the Scanner - Medtronic, Abbott Laboratories, Stryker, Zeltiq Aesthetics, and EnteroMedics
5. Treatment of Type 2 Diabetes Mellitus added to EnteroMedics CE Mark for Obesity
6. EnteroMedics to Host Fourth Quarter 2014 Financial Results and Commercialization Update Conference Call
7. EnteroMedics Reports Fourth Quarter 2014 Financial Results
8. EnteroMedics to Present at Upcoming Investor Conferences
9. EnteroMedics Announces Partnership with American HealthCare Lending to Support Patient Access and Enhance Affordability of vBloc Therapy
10. EnteroMedics Announces Update on vBloc Therapy Trained Centers and Physicians
11. EnteroMedics Reports First Quarter 2015 Financial Results and Provides Business Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2018)... ... October 12, 2018 , ... ... open, welcoming applications from healthcare providers, students, trainees, and researchers worldwide. Winning proposals ... as microbiome sequencing and bioinformatics services. , “uBiome is thrilled to further expand ...
(Date:10/13/2018)... ... October 12, 2018 , ... David Young was the ... used in the Lockheed F22 Aircraft. Today, he announces the invention of the ... can lead to sudden cardiac death (SCD). , The Two-Dimensional Arrhythmia Monitor has ...
(Date:10/13/2018)... ... October 13, 2018 , ... In the world of contract manufacturing, Ion ... after another. 2018 has been a game-changing year for Ion Labs . Expansions ... role in the growth. Ion Labs attributes its growth to its responsiveness to customer ...
Breaking Medicine Technology:
(Date:10/18/2018)... ... 18, 2018 , ... Fellow Health Partners, Inc. , a New York ... who have agreed to join its Advisory Board. , CEO Michael N. Brown said, ... helping to guide Fellow Health Partners. They will provide strategic as well as tactical, ...
(Date:10/17/2018)... ... October 17, 2018 , ... Power to Decide, the campaign to prevent ... program. Made possible with support from the HHS Office of Adolescent Health, Innovation ... 21st century through a focus on technology-enabled ideas. , This year, five new teams ...
(Date:10/17/2018)... ... October 17, 2018 , ... A new ... Rights identifies best practices in the management of lesbian, bisexual, gay, transgender, questioning, ... youth are overrepresented in the juvenile justice system, especially lesbian and bisexual girls ...
(Date:10/16/2018)... ... October 16, 2018 , ... CCC ( Compressor Controls Corporation ... operators today announces Total Train Comprehensive Release version 14.1 (TTCR 14.1), available for ... focused on improving cybersecurity defense around turbomachinery. The upgrade process is seamless, ...
(Date:10/16/2018)... ... 16, 2018 , ... With a petition (case CJ-2018-04177) filed last week in ... a series of lawsuits filed in states around the country against Massage Envy that ... by Massage Envy’s massage therapists. , This lawsuit alleges that the company's corporate ...
Breaking Medicine News(10 mins):